Tipsheet
What matters at India’s listed companies
Earnings · Chemicals · Small cap

Fischer's consolidated profit of ₹310 cr hides a standalone loss of ₹104 cr

Full-year consolidated revenue tripled to ₹3,086 crore, but the core business lost money and Q4 swung to a ₹71 crore loss.


Mkt cap₹2,478 cr
P/E62.81×
ROE0.44%
Debt / eq.0.18
Div yld0.01%
₹104 cr Full-year standalone net loss, versus a ₹6.6 cr profit last year.

What's new

  • Consolidated Q4 net loss of ₹71 crore, swinging from a ₹13 crore profit a year ago.
  • FY26 standalone operations posted a ₹104 crore loss, reversing a ₹6.6 crore profit.
  • Board recommended a final dividend of 5 paise per share.

Why this matters

The consolidated growth is all subsidiary. The parent is bleeding. A ₹71 crore loss in the final quarter means the full-year profit of ₹310 crore came with a significant profitability collapse at the end of the year. The standalone numbers expose the core business as unprofitable and worsening.

What we're watching

  • The expense breakdown that drove the Q4 swing to a loss.
  • Management's plan to fix the standalone operation's ₹104 crore loss.
  • Whether the 5 paise dividend is sustainable.

The full read

Fischer's FY26 is two companies. Consolidated, revenue tripled to ₹3,086 crore and profit hit ₹310 crore. The final quarter was a ₹71 crore loss. The core is a different picture. Standalone, Fischer lost ₹104 crore for the year, against a ₹6.6 crore profit. The consolidated gains are a product of subsidiary scaling. The standalone business is unprofitable. The board declared a 5-paise dividend. That masks the cash burn.

Questions answered

Why did Fischer swing to a Q4 loss despite strong full-year growth?
Expenses surged in the quarter, though the filing does not specify the drivers. For the full year, consolidated revenue jumped to ₹3,086 crore, but profitability collapsed in the final quarter.
What explains the gap between consolidated profit and standalone loss?
Consolidated, the company made ₹310 crore. Standalone, it lost ₹104 crore. The consolidated gains are almost entirely from subsidiary activity, not the parent entity.
Is the revenue growth sustainable?
FY26 consolidated revenue was ₹3,086 crore, up 179% from ₹1,107 crore. The open question is whether this growth is driven by the core business, which is now losing money, or by subsidiary activity.
Mentioned: Fischer Medical Ventures · ₹3,086 cr consolidated revenue · ₹104 cr standalone loss
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.